Cargando…

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawada, Yu, Sakai, Mayuko, Yoshikawa, Toshiaki, Ofuji, Kazuya, Nakatsura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518534/ https://www.ncbi.nlm.nih.gov/pubmed/23243625 http://dx.doi.org/10.4161/onci.21351

Ejemplares similares

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3
por: Kawashima, Issei, et al.
Publicado: (2015)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
por: Ukai, Mayu, et al.
Publicado: (2021)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens
por: Aruga, Atsushi
Publicado: (2013)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Tricking an ancient immune function to eradicate hepatocellular carcinoma
por: Miyazaki, Toru, et al.
Publicado: (2015)

YES, a novel therapeutic target in hepatocellular carcinoma
por: Lapouge, Marjorie, et al.
Publicado: (2022)

Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015)

KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma
por: Cariani, Elisabetta, et al.
Publicado: (2013)

Cisd2 haploinsufficiency: A driving force for hepatocellular carcinoma
por: Shen, Zhao-Qing, et al.
Publicado: (2018)

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)

Impact of multiplicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma
por: Tanimine, Naoki, et al.
Publicado: (2015)

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
por: Binder, David C, et al.
Publicado: (2013)

Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma development
por: Yevsa, Tetyana, et al.
Publicado: (2012)

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
por: Dosset, Magalie, et al.
Publicado: (2013)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored?
por: Lugade, Amit A, et al.
Publicado: (2013)

NKT cell adjuvants in therapeutic vaccines against hematological cancers
por: Mattarollo, Stephen R., et al.
Publicado: (2013)

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
por: Sayem, Mohammad A., et al.
Publicado: (2015)

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice
por: Lee, YoungHee, et al.
Publicado: (2012)

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
por: Charneau, Jimmy, et al.
Publicado: (2021)

DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma
por: Ji, Jie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qqsg3u0oc2s29c68hkt44jma1p